TissUse GmbH

Activities: Research & Development Analysis

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Research & Development

PMI and TissUse collaborate on human aerosol test platform

The companies aim to combine their complementary technologies and expertise
Media

TissUse establishes a multi-organ model for risk assessment with Bayer

The biotechnology company has signed a collaboration agreement with the pharmaceutical and life sciences company to develop a liver-endocrine tissue assay
Research & Development

Miniaturised organ equivalents for drug testing

Dr Reyk Horland, VP Business Development of TissUse, speaks to Angharad Baldwin of <i>Manufacturing Chemist</i> about a powerful new tool that has the potential to predict toxicity or efficacy early on in the drug development process
Research & Development

TissUse reports progress made in collaboration with AstraZeneca

TissUse continues its successful collaboration with AstraZeneca to establish relevant microphysiological system (MPS) models based on TissUse’s multi-organ-chip technology
Subscribe now